

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
22-192

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION CLINICAL STUDIES

NDA/Serial Number: 22-192 / N000
Drug Name: Iloperidone
Indication(s): Treatment of Schizophrenia
Applicant: Vanda Pharmaceuticals
Date(s): Received: Sept 27, 2007;
PDUFA Due Date: July 27, 2007
Review Priority: Standard
Biometrics Division: Biometrics I, HFD-710
Statistical Reviewers: Phillip Dinh, Ph.D.
Concurring Reviewers: Peiling Yang, Ph.D.
H.M. James Hung, Ph.D.
Sue-Jane Wang, Ph.D.
Medical Division: Division of Psychiatric Products, HFD-130
Clinical Team: Michelle Chuen M.D., Medical Reviewer, HFD-130
Ni Khin M.D., Medical Team Leader, HFD-130
Project Manager: Kimberly Updegraff, M.S., R.Ph., HFD-130

Keywords: Clinical studies; NDA review; Pharmacogenomics; Subgroup analyses

Table of Contents

1. EXECUTIVE SUMMARY	6
1.1 CONCLUSIONS AND RECOMMENDATIONS	6
1.2 BRIEF OVERVIEW OF CLINICAL STUDIES	6
1.3 STATISTICAL ISSUES AND FINDINGS	7
2. INTRODUCTION	9
2.1 OVERVIEW	9
2.2 DATA SOURCES	9
3. STATISTICAL EVALUATION	10
3.1 EVALUATION OF EFFICACY	10
3.1.1 Study ILP3004ST	10
3.1.1.1 Objectives	10
3.1.1.2 Study Design	10
3.1.1.3 Efficacy Endpoints and Analyses	11
3.1.1.4 Efficacy Results	11
3.1.1.4.1 Study Population	11
3.1.1.4.2 Sponsor's Efficacy Results for Primary Endpoint	13
3.1.1.4.3 Reviewer's Results and Comments	13
3.1.2 Study ILP3005ST	14
3.1.2.1 Objectives	14
3.1.2.2 Study Design	14
3.1.2.3 Efficacy Endpoints and Analyses	15
3.1.2.4 Efficacy Results	16
3.1.2.4.1 Study Population	16
3.1.2.4.2 Sponsor's Efficacy Results for Primary Endpoint	17
3.1.2.4.3 Sponsor's Efficacy Results for the CNTF subgroup	18
3.1.2.4.4 Reviewer's Results and Comments	19
3.1.3 Study VP-VYV-683-3101	22
3.1.3.1 Objectives	22
3.1.3.2 Study Design	23
3.1.3.3 Efficacy Endpoints and Analyses	23
3.1.3.4 Efficacy Results	24
3.1.3.4.1 Study Population	24
3.1.3.4.2 Sponsor's Efficacy Results for Primary Endpoint	25
3.1.3.4.3 Sponsor's Efficacy Results for Key Secondary Endpoint	25
3.1.3.4.4 Sponsor's Other Efficacy Results	26
3.1.3.4.5 Reviewer's Results and Comments	28
3.1.4 Study ILP3000ST	28
3.1.5 Studies ILP3001, ILP3002, ILP3003	29
3.2 EVALUATION OF SAFETY	30
4. FINDINGS IN SPECIAL/SUBGROUP POPULATIONS	30
4.1 GENDER, RACE AND AGE	30
4.1.1 Study ILP3004ST	30
4.1.1.1 Gender	30
4.1.1.2 Race	31
4.1.1.3 Age	31
4.1.2 Study ILP3005ST	31
4.1.2.1 Gender	31
4.1.2.2 Race	32
4.1.2.3 Age	32
4.1.3 Study VP-VYV-683-3101	33
4.1.3.1 Gender	33
4.1.3.2 Race	33

4.1.3.3	Age	34
4.2	OTHER SUBGROUPS	34
4.2.1	<i>Study ILP3004ST</i>	34
4.2.1.1	<i>U.S.A. versus non-U.S.A.</i>	34
4.2.2	<i>Study ILP3005ST</i>	34
4.2.2.1	<i>U.S.A. versus non-U.S.A.</i>	34
4.2.3	<i>Study VP-VYV-683-3101</i>	35
5.	SUMMARY AND CONCLUSIONS	35
5.1	STATISTICAL ISSUES AND COLLECTIVE EVIDENCE	35
5.2	CONCLUSIONS AND RECOMMENDATIONS	36
6.	APPENDIX	38
6.1	STUDY ILP3000ST	38
6.2	STUDY ILP3004ST	40
6.3	STUDY ILP3005ST	41

LIST OF TABLES

Table 1. Dosing schedule for the 6-week initial double-blind phase.....	10
Table 2. Study ILP3004ST: disposition of patients	12
Table 3. Study ILP3004ST: demographic and baseline disease characteristics (randomized sample).....	12
Table 4. Study ILP3004ST: sponsor's primary efficacy results: change from endpoint to baseline in BPRS total score (LOCF) in the MITT sample	13
Table 5. Study ILP3004ST: reviewer's primary efficacy results: change from endpoint to baseline in BPRS total score (LOCF) (excluding schizoaffective patients); MITT sample	13
Table 6. Study ILP3004ST: Adjusted mean change from baseline up to end of week 6 in the BPRS total score (LOCF) (excluding schizoaffective patients); MITT sample	14
Table 7. Study ILP3005ST: disposition of patients	16
Table 8. Study ILP3005ST: demographic and baseline disease characteristics (randomized sample).....	17
Table 9. Study ILP3005ST: sponsor's primary efficacy results: change from endpoint to baseline in BPRS total score (LOCF) in the MITT sample	17
Table 10. Study ILP3005ST: Sponsor's Efficacy Results by genetic subgroups: Change from baseline at Week 6: ANCOVA (LOCF) analysis (PG Population).....	18
Table 11. Study ILP3005ST: Reviewer's Efficacy Results by genetic subgroups: Change from baseline at Week 6: ANCOVA (LOCF) analysis (PG Population)	19
Table 12. Study ILP3005ST: Reviewer's Efficacy Results by genetic subgroups: Change from baseline at Week 6: ANCOVA (LOCF) analysis (PG Population-Schizophrenia sample).....	19
Table 13. Study ILP3005ST: reviewer's primary efficacy results: change from endpoint to baseline in BPRS total score (LOCF) (excluding schizoaffective patients); MITT sample	20
Table 14. Study ILP3005ST: Adjusted mean change from baseline up to end of week 6 in the BPRS total score (LOCF) (excluding schizoaffective patients); MITT sample	20
Table 15. Study ILP3005ST: reviewer's efficacy results: change from endpoint to baseline in BPRS total score (OC) (excluding schizoaffective patients); MITT sample	20
Table 16. Study ILP3005ST: reviewer's MMRM results: change from endpoint to baseline in BPRS total score (OC) (excluding schizoaffective patients); MITT sample	21
Table 17. Study ILP3005ST: reviewer's efficacy results: change from endpoint to baseline in PANSS total score (LOCF) (excluding schizoaffective patients); MITT sample	21
Table 18. Study ILP3005ST: reviewer's efficacy results: change from endpoint to baseline in BPRS total score (LOCF) (excluding schizoaffective patients); MITT sample; Pre- versus Post-dose modification	22
Table 19. Study VP-VYV-683-3101: disposition of patients (randomized sample)	24
Table 20. Study VP-VYV-683-3101: demographic and baseline disease characteristics (randomized sample).....	25
Table 21. Study VP-VYV-683-3101: Sponsor's Primary Efficacy Results: Change from Baseline in PANSS total score in the MITT sample.....	25
Table 22. Study VP-VYV-683-3101: Reviewer's Primary Efficacy Results by genetic subgroups: Change from Baseline in PANSS total score in the MITT sample.....	26
Table 23. Study VP-VYV-683-3101: Sponsor's Efficacy Results: Change from Baseline in BPRS total score in the MITT sample	26
Table 24. Study VP-VYV-683-3101: Adjusted mean change from baseline up to end of week 6 in the PANSS total score, MMRM analysis; MITT sample.....	27
Table 25. Study VP-VYV-683-3101: Sponsor's Primary Efficacy Sensitivity Analysis: Change from Baseline in PANSS total score in the MITT sample (LOCF).....	27
Table 26. Study VP-VYV-683-3101: Reviewer's Efficacy Results by genetic subgroups: Change from Baseline in PANSS total score in the MITT sample (LOCF)	27
Table 27. Study VP-VYV-683-3101: Sponsor's Primary Efficacy Sensitivity Analysis: Change from Baseline in PANSS total score in the OC sample.....	28
Table 28. Study VP-VYV-683-3101: Reviewer's Primary Efficacy Results: Change from Baseline in PANSS total score in the MITT sample (Site #032 excluded).....	28
Table 29. Study ILP3004ST: reviewer's primary efficacy results by gender: change from endpoint to baseline in BPRS total score (LOCF) (excluding schizoaffective patients); MITT sample	31

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.